Option Care Health Sees Unusually High Options Volume (NASDAQ:OPCH)

Option Care Health, Inc. (NASDAQ:OPCH) was the target of some unusual options trading on Wednesday. Traders acquired 2,128 call options on the company. This is an increase of approximately 2,560% compared to the average daily volume of 80 call options.

NASDAQ OPCH opened at $21.37 on Friday. The stock has a market cap of $3.84 billion, a PE ratio of 427.49 and a beta of 1.11. The company’s 50 day moving average price is $18.69. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.58 and a quick ratio of 1.17. Option Care Health has a 1-year low of $10.52 and a 1-year high of $22.69.

Option Care Health (NASDAQ:OPCH) last announced its earnings results on Thursday, May 6th. The company reported ($0.02) EPS for the quarter, missing the Zacks’ consensus estimate of $0.02 by ($0.04). Option Care Health had a return on equity of 0.92% and a net margin of 0.29%. The company had revenue of $759.20 million during the quarter, compared to analysts’ expectations of $752.47 million. During the same quarter last year, the firm posted ($0.11) EPS. Option Care Health’s revenue for the quarter was up 7.6% compared to the same quarter last year. Equities analysts predict that Option Care Health will post 0.36 EPS for the current fiscal year.

In related news, Director Harry M. Jansen Kraemer, Jr. acquired 40,000 shares of the stock in a transaction on Wednesday, May 19th. The stock was purchased at an average price of $17.59 per share, for a total transaction of $703,600.00. Following the completion of the transaction, the director now owns 83,760 shares of the company’s stock, valued at approximately $1,473,338.40. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Timothy P. Sullivan sold 12,000,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 17th. The shares were sold at an average price of $20.00, for a total value of $240,000,000.00. The disclosure for this sale can be found here. Insiders have acquired a total of 53,355 shares of company stock valued at $922,938 in the last ninety days. Insiders own 47.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of OPCH. BlackRock Inc. raised its position in Option Care Health by 66.7% during the 1st quarter. BlackRock Inc. now owns 6,084,403 shares of the company’s stock valued at $107,935,000 after purchasing an additional 2,434,741 shares in the last quarter. Park West Asset Management LLC grew its stake in Option Care Health by 57.6% during the 4th quarter. Park West Asset Management LLC now owns 6,302,202 shares of the company’s stock worth $98,566,000 after buying an additional 2,302,202 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Option Care Health by 49.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,257,384 shares of the company’s stock worth $111,006,000 after buying an additional 2,068,169 shares during the last quarter. Nuveen Asset Management LLC grew its stake in Option Care Health by 179.0% during the 1st quarter. Nuveen Asset Management LLC now owns 2,640,085 shares of the company’s stock worth $46,835,000 after buying an additional 1,693,761 shares during the last quarter. Finally, Luminus Management LLC purchased a new position in Option Care Health during the 1st quarter worth $27,266,000. 47.61% of the stock is owned by institutional investors and hedge funds.

OPCH has been the subject of a number of recent analyst reports. Canaccord Genuity upped their target price on Option Care Health from $20.00 to $24.00 and gave the company a “buy” rating in a report on Friday, March 12th. Barrington Research raised Option Care Health to an “outperform” rating and upped their price target for the stock from $19.00 to $24.00 in a research note on Friday, March 12th. Deutsche Bank Aktiengesellschaft increased their target price on Option Care Health from $22.00 to $23.50 and gave the stock a “buy” rating in a research note on Friday, March 12th. Finally, Zacks Investment Research cut Option Care Health from a “hold” rating to a “sell” rating in a research note on Tuesday, June 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $20.94.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides immunoglobulin infusion therapies for the treatment of immune deficiencies; anti-infective therapies and services; home infusion services to treat heart failures; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders; and immunoglobulin infusion therapies.

Recommended Story: What’s a Black Swan?

Receive News & Ratings for Option Care Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Option Care Health and related companies with MarketBeat.com's FREE daily email newsletter.